<DOC>
	<DOCNO>NCT01360996</DOCNO>
	<brief_summary>The classic description polycystic ovary syndrome ( PCOS ) disorder characterize menstrual irregularity , chronic anovulation , androgen excess , abnormal gonadotropin secretion . Use combine oral contraceptive ( OCs ) woman PCOS effectively reduce circulate androgen . Although OCs common one old symptomatic treatment modality androgenic skin symptom irregular menstrual cycle cause hyperandrogenism , data concern effect treatment PCOS woman different body mass index ( BMI ) limit . This study do compare hormone metabolic change treatment low-dose oral birth control regimen DRSP 3 mg/EE 0.02mg/levomefolate calcium 0.451 mg ( Beyaz™ ) woman PCOS different body weight .</brief_summary>
	<brief_title>Low Dose OC Therapy Women With Polycystic Ovary Syndrome ( PCOS ) : Impact BMI Hyperandrogenism</brief_title>
	<detailed_description>Clinically , polycystic ovary syndrome ( PCOS ) heterogeneous disorder functional androgen excess feature PCOS run spectrum severity . The optimal modality long-term treatment PCOS positively influence androgen synthesis , sex hormone bind globulin ( SHBG ) production , insulin sensitivity , lipid profile , clinical symptom include hirsutism irregular menstrual cycle . Combined oral contraceptive key component chronic treatment woman PCOS ; improve androgen excess regulate menstrual cycle . The effect OCs ovarian folliculogenesis significantly decrease androgen production . This mechanism confirm healthy woman woman PCOS . In obese patient PCOS , likely suppression androgen production significant . It thus possible hypothesize effect OCs PCOS could dependent body weight need head-to-head comparison . The aim study compare effect 6 month low-dose oral contraceptive regimen 24/4 DRSP 3 mg/EE 0.02mg/levomefolate calcium 0.451 mg androgen profile , cardiometabolic measure , B-vitamin status , menstrual cycle regulation three group , normal ( BMI 18-24.9 kg/ m2 ) overweight ( BMI 25-29.9 kg/ m2 ) obese ( BMI 30-35 kg/ m2 ) woman PCOS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>•Adult female16 year 35 year age diagnose PCOS desire contraception Actual BMI &gt; 18 &lt; 35kg/ m2 Written consent participation study Patient complete lactation Metabolic abnormalities require pharmacological intervention ( except control thyroid disease ) Uncontrolled hypertension Cancer history hormonedependent cancer History cholestasis Presence contradiction OC administration Personal history cardiovascular event . Use drug know exacerbate glucose tolerance . No prescription overthecounter weightloss drug Diabetes Use medication affect blood pressure lipid profile Smoking past 6 month Known thrombogenic mutation ( e.g . Factor V Leiden ) Current history deep venous thrombosis/pulmonary embolism Major surgery prolong immobilization Injectable hormonal contraceptive use within 6 month Use hormonal ( e.g. , oral contraceptive [ OC ] pill ) insulinsensitizing medication unless willing cease medication 3 month study measurement</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PCOS</keyword>
</DOC>